Aerosol Medication Use in COVID-19 Pandemic
Yıl: 2020 Cilt: 18 Sayı: 2 Sayfa Aralığı: 110 - 112 Metin Dili: İngilizce DOI: 10.21911/aai.539 İndeks Tarihi: 05-06-2021
Aerosol Medication Use in COVID-19 Pandemic
Öz: Administration of aerolized drugs to patients diagnosed with COVID-19 leads to the risk of transmission of patient-generated infectiousaerosols to healthcare providers.While the COVID-19 pandemic is ongoing, in order to provide the best treatment for patients and atthe same time to protect healthcare providers at the highest level, it is necessary to increase access to information and pay maximumattention to preventive measures.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Editöre Mektup Erişim Türü: Erişime Açık
- 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506.
- 2. https://www.who.int/news-room/q-a-detail/q-a-coronaviruses. (Accessed April 3, 2020.)
- 3. Respiratory Therapy Group, Respiratory Medicine Branch, Chinese Medical Association. Expert consensus on protective measures related to respiratory therapy in patients with severe and critical coronavirus infection. Chinese Journal of Tuberculosis and Respiratory Diseases, 2020,17(00):E020 -E020. DOI: 10.3760 / cma.j.issn.1001-0939.2020.0020
- 4. www.ginasthma.org. (Accessed April 23, 2020.)
- 5. Asthma and Allergy Foundation of America- www.aafa.org (Accessed May 17, 2020.)
- 6. https://www.nationalasthma.org.au/news/2020/covid-19-andyour-asthma-patients. (Accessed May 29, 2020.)
- 7. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: A systematic review. PLoS One 2012;7(4):e35797.
- 8. Rau JL, Ari A, Restrepo RD. Performance comparison of nebulizer designs: Constant-output, breath-enhanced, and dosimetric. Respir Care 2004;49(2):174-9.
- 9. Ari A. Practical strategies for a safe and effective delivery of aerosolizedmedications to patients with COVID-19. Respiratory Medicine 2020;167:105987.
- 10. McGrath J, O’Toole C, GB, Joyce M, Byrne M, MacLoughlin R. Investigation of fugitive aerosols released into the environment during high-flow therapy. Pharmaceutics 2019;11:254.
- 11. Wittgen BP, Kunst PW, Perkins WR, Lee JK, Postmus PE. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med 2006;19(3):385- 391.
- 12. Ari A, Fink JB, Pilbeam S. Secondhand aerosol exposure during mechanical ventilation with and without expiratory filters: An in-vitro study. Ind J Resp Care 2016; 5(1): 677-82.
- 13. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: Low risk of bio-aerosol dispersion. Eur Respir J 2020;55(5):2000892.
- 14. Hess DR. Medicated Aerosol Delivery Devices. In: Volsko TA, Chatburn RL, El-Khatib MF (eds). Equipment for Respiratory Care. Burlington, Massachusetts: Jones & Bartlett Learning; 2014:527-552.
- 15. Hess DR. Humidity and aerosol therapy. In: Hess DR, MacIntyre NR, Galvin WF, Mishoe SC. (eds). Respiratory Care Principles and Practice, 4th ed. Burlington: Jones and Bartlett Learning, 2020: 321-65.
- 16. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002;47(12):1406-18.
- 17. Miller A, Epstein D. Safe bronchodilator treatment in mechanically ventilated COVID-19 patients: A single center experience. J Crit Care 2020;58:56-7.
- 18. Ari A, Fink J, Harwood R, Pilbeam S. Secondhand aerosol exposure during mechanical ventilation with and without expiratory filters: An in-vitro study. Indian Journal of Respiratory Care 2016;5:677-82.
- 19. Sutherasan Y, Ball L, Raimondo P, Caratto V, Sanguineti E, Costantino F, et al. Effects of ventilator settings, nebulizer and exhalation port position on albuterol delivery during non-invasive ventilation: An in-vitro study. BMC Pulm Med 2017;17(1):9.
- 20. Ari A. How to optimize aerosol drug delivery during noninvasive ventilation: What to use, how to use it, and why?. Eurasian J Pulmonol 2019;21:1-8.
- 21. Adir Y, Segol O, Kompaniets D, Ziso H, Yaffe Y, Bergman I, et al. COVID-19: Minimising risk to healthcare workers during aerosol-producing respiratory therapy using an innovative constant flow canopy. Eur Respir J 2020; 55: 2001017.
| APA | Topel M, Aksu K (2020). Aerosol Medication Use in COVID-19 Pandemic. , 110 - 112. 10.21911/aai.539 |
| Chicago | Topel Musa,Aksu Kurtuluş Aerosol Medication Use in COVID-19 Pandemic. (2020): 110 - 112. 10.21911/aai.539 |
| MLA | Topel Musa,Aksu Kurtuluş Aerosol Medication Use in COVID-19 Pandemic. , 2020, ss.110 - 112. 10.21911/aai.539 |
| AMA | Topel M,Aksu K Aerosol Medication Use in COVID-19 Pandemic. . 2020; 110 - 112. 10.21911/aai.539 |
| Vancouver | Topel M,Aksu K Aerosol Medication Use in COVID-19 Pandemic. . 2020; 110 - 112. 10.21911/aai.539 |
| IEEE | Topel M,Aksu K "Aerosol Medication Use in COVID-19 Pandemic." , ss.110 - 112, 2020. 10.21911/aai.539 |
| ISNAD | Topel, Musa - Aksu, Kurtuluş. "Aerosol Medication Use in COVID-19 Pandemic". (2020), 110-112. https://doi.org/10.21911/aai.539 |
| APA | Topel M, Aksu K (2020). Aerosol Medication Use in COVID-19 Pandemic. Astım Allerji İmmünoloji, 18(2), 110 - 112. 10.21911/aai.539 |
| Chicago | Topel Musa,Aksu Kurtuluş Aerosol Medication Use in COVID-19 Pandemic. Astım Allerji İmmünoloji 18, no.2 (2020): 110 - 112. 10.21911/aai.539 |
| MLA | Topel Musa,Aksu Kurtuluş Aerosol Medication Use in COVID-19 Pandemic. Astım Allerji İmmünoloji, vol.18, no.2, 2020, ss.110 - 112. 10.21911/aai.539 |
| AMA | Topel M,Aksu K Aerosol Medication Use in COVID-19 Pandemic. Astım Allerji İmmünoloji. 2020; 18(2): 110 - 112. 10.21911/aai.539 |
| Vancouver | Topel M,Aksu K Aerosol Medication Use in COVID-19 Pandemic. Astım Allerji İmmünoloji. 2020; 18(2): 110 - 112. 10.21911/aai.539 |
| IEEE | Topel M,Aksu K "Aerosol Medication Use in COVID-19 Pandemic." Astım Allerji İmmünoloji, 18, ss.110 - 112, 2020. 10.21911/aai.539 |
| ISNAD | Topel, Musa - Aksu, Kurtuluş. "Aerosol Medication Use in COVID-19 Pandemic". Astım Allerji İmmünoloji 18/2 (2020), 110-112. https://doi.org/10.21911/aai.539 |
